IDH1 and central nervous system cancer: In an in vitro experiment, after treatment with TMZ, the α-ketoglutarate and glutamate levels were found to be significantly lower than those in untreated glioma cells, indicating that 1H MRS may be a potential assessment tool for assessing the response to TMZ treatment in IDH1-mutant gliomas (28).